BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bevacizumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Bevacizumab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03743662-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT03743662)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Nivolumab With Radiation Therapy
  and Bevacizumab for Recurrent MGMT Methylated Glioblastoma\nEstimated pri
 mary completion: November 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT03743662
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04958811-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT04958811)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tir
 agolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced
  Non-squamous NSCLC\nEstimated primary completion: November 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04958811
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05991102-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Bevacizumab: Phase na readout est. (NCT05991102)
DESCRIPTION:Bevacizumab\, phase na\, Colorectal Cancer.\nStudy: Amplitude M
 odulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-
 102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer\n
 Estimated primary completion: November 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05991102
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06160206-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06160206)
DESCRIPTION:Bevacizumab\, phase 2\, Recurrent Glioblastoma.\nStudy: Retifan
 limab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment
  of Recurrent Glioblastoma\nEstimated primary completion: 30 November 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06160206
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01871766-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT01871766)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Risk-Adapted Focal Proton Beam R
 adiation and/or Surgery in Patients With Low\, Intermediate and High Risk 
 Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT01871766
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03786692-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT03786692)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Pha
 se II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizum
 ab in Stage IV NSCLC\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT03786692
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05281471-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05281471)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: Efficacy & Safe
 ty of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's 
 Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ov
 arian Cancer (PRROC) (OnPrime\, GOG-3076)\nEstimated primary completion: D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaciz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05281471
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05654454-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05654454)
DESCRIPTION:Bevacizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A S
 afety and Efficacy Study of Bevacizumab\, Paclitaxel\, Carboplatin Compare
 d to Avastin® in Non-Small Cell Lung Cancer\nEstimated primary completion
 : December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/beva
 cizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05654454
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06107413-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06107413)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Study to Ass
 ess Adverse Events and Change in Disease Activity in Previously Treated Ad
 ult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Met
 astatic Colorectal Cancer in Combination With IV Fluorouracil\, Folinic Ac
 id\, and Bevacizumab\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06107413
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06607458-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06607458)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Evaluation o
 f the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directl
 y Into the Liver Followed by Treatment w/Approved Cancer Treatment or Appr
 oved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/
 Liver Dominant Disease\nEstimated primary completion: December 2026. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06607458
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06840002-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06840002)
DESCRIPTION:Bevacizumab\, phase 1/2\, Ovarian Cancer.\nStudy: A Clinical St
 udy of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurre
 nt Ovarian Cancer\nEstimated primary completion: December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06840002
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06844474-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06844474)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC\nE
 stimated primary completion: December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06844474
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07233850-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07233850)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Phase II C
 linical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gast
 rointestinal Cancers\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07233850
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07512674-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07512674)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Modified Sho
 rt-Course Radiotherapy Combined With Immunochemotherapy and Targeted Thera
 py as First-Line Treatment for MSS Metastatic Colorectal Cancer\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07512674
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06683703-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06683703)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Uti
 delone Injection Combined with Bevacizumab Injection for Non-small Cell Lu
 ng Cancer Patients with Brain Metastases\nEstimated primary completion: 1 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaci
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06683703
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07090525-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07090525)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Bevacizumab Combined With Cispla
 tin Versus Cisplatin Monotherapy in Malignant Serous Effusions\nEstimated 
 primary completion: 1 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07090525
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07192185-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07192185)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Syste
 mic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients 
 With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab\nEsti
 mated primary completion: 1 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07192185
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446452-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261206
DTEND;VALUE=DATE:20261207
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07446452)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Disitamab Vedotin Plus Bevacizum
 ab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II St
 udy\nEstimated primary completion: 6 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07446452
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06571422-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06571422)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: Phase I Study of WJ47156 Monothe
 rarpy and in Combination With Other Therapy in Advanced Solid Tumors\nEsti
 mated primary completion: 15 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06571422
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06801730-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06801730)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Irinotecan Liposomes Combined Wi
 th Bevacizumab in the Treatment of Recurrent Glioma\nEstimated primary com
 pletion: 15 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06801730
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05843188-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05843188)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Study of Hyd
 roxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colore
 ctal Cancer\nEstimated primary completion: 24 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05843188
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06783647-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06783647)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A C
 linical Trial of LBL-024 Combination Drug in Patients With Advanced Solid 
 Tumours[Substudy 01(NSCLC)]\nEstimated primary completion: 24 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06783647
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05588388-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05588388)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Study of Bevacizumab in Combinat
 ion With Chemoimmunotherapy and Atezolizumab in Patients With Extensive St
 age Small Cell Lung Cancer and Liver Metastases\nEstimated primary complet
 ion: 28 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05588388
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05171660-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05171660)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: Combination 
 With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Me
 tastatic Colorectal Cancer\nEstimated primary completion: 30 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05171660
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05398861-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05398861)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Utidelone Combined With Bevacizu
 mab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Canc
 er\nEstimated primary completion: 30 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05398861
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06031285-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06031285)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Perio
 perative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Pati
 ents With PVTT: A Phase-2 Clinical Trial\nEstimated primary completion: 30
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevac
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06031285
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465563-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06465563)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: SHR-8068 in Combination With Ade
 brelimab\, Bevacizumab\, and Platinum-Based Chemotherapy as First-line Tre
 atment in Patients With Advanced Biliary Tract Cancer\nEstimated primary c
 ompletion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06465563
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06982924-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06982924)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A C
 linical Study on the Efficacy and Safety of the Combination of Limertinib 
 and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.\nEsti
 mated primary completion: 30 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06982924
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007767-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07007767)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Exploring Si
 ntilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cance
 r (After 2+ Prior Therapies）\nEstimated primary completion: 30 December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0700776
 7
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340164-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07340164)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Trastzumab Deru
 xtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhib
 itor Therapy\nEstimated primary completion: 30 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07340164
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02210117-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT02210117)
DESCRIPTION:Bevacizumab\, phase 1\, Renal Cell Carcinoma.\nStudy: Nivolumab
  With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Pati
 ents With Metastatic Kidney Cancer That Can Be Removed by Surgery\nEstimat
 ed primary completion: 31 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT02210117
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03303495-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT03303495)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: A Study of 2
 nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC\nEsti
 mated primary completion: 31 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03303495
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03401294-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT03401294)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Conversion F
 rom Unresectable To Resectable Metastatic Colorectal Cancer.\nEstimated pr
 imary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03401294
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03937830-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT03937830)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Combi
 ned Treatment of Durvalumab\, Bevacizumab\, Tremelimumab and Transarterial
  Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Bil
 iary Tract Carcinoma\nEstimated primary completion: 31 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03937830
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05460767-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT05460767)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: Safety\, Tolerability and Prelim
 inary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphom
 a\nEstimated primary completion: 31 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05460767
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05488522-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT05488522)
DESCRIPTION:Bevacizumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: SBRT 
 With Atezo/Bev for HCC\nEstimated primary completion: 31 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05488522
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05636111-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT05636111)
DESCRIPTION:Bevacizumab\, phase 1\, Ovarian Cancer.\nStudy: Phase 1b of Lur
 binectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platin
 um-resistant Ovarian Cancer\nEstimated primary completion: 31 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05636111
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05727163-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05727163)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: FOLFOX Via H
 AI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic
  FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutat
 ed CRLM Patients\nEstimated primary completion: 31 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05727163
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05844046-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05844046)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Seque
 ntial or Up-front Triple Treatment With Durvalumab\, Tremelimumab and Beva
 cizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients\nEstima
 ted primary completion: 31 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05844046
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05848739-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT05848739)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: A Phase 1-2 of ST316 With Select
 ed Advanced Unresectable and Metastatic Solid Tumors\nEstimated primary co
 mpletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05848739
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05867420-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05867420)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: A Study of ASKG915 in Patients
  With Selected Advanced Solid Tumors.\nEstimated primary completion: 31 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05867420
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06011109-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06011109)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: Treatment of Patients With Rec
 urrent High-Grade Glioma With APG-157 and Bevacizumab\nEstimated primary c
 ompletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06011109
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06280495-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT06280495)
DESCRIPTION:Bevacizumab\, phase 2/3\, Colorectal Cancer.\nStudy: Neoadjuvan
 t Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT\, 
 pMMR/MSS CRC Patients\nEstimated primary completion: 31 December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06280495
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06292286-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase na readout est. (NCT06292286)
DESCRIPTION:Bevacizumab\, phase na\, Ovarian Cancer.\nStudy: Secondary Inte
 rval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovar
 ian Cancer\nEstimated primary completion: 31 December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06292286
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06433869-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06433869)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: The Efficacy of Bevacizumab and 
 Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rm
 hTNF-NC) in the Treatment of Malignant Ascites\nEstimated primary completi
 on: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06433869
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06696768-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06696768)
DESCRIPTION:Bevacizumab\, phase 1\, Colorectal Cancer.\nStudy: Clinical Tri
 al of an Anti-cancer Drug\, CA-4948 (Emavusertib)\, in Combination With Ch
 emotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Ca
 ncer\nEstimated primary completion: 31 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06696768
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007728-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07007728)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Iparomlimab/
 Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy fo
 r Colorectal Cancer Liver Metastasis\nEstimated primary completion: 31 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7007728
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07359404-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07359404)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Sacituzumab Govitecan Plus Bevac
 izumab in Metastatic TNBC\nEstimated primary completion: 31 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07359404
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05828459-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT05828459)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: First-in-human Study of OT-A201 
 in Patients With Selected Hematological Malignancies and Solid Tumors\nEst
 imated primary completion: January 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05828459
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623577-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07623577)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Sac-TMT Combined With Bevacizuma
 b in TNBC With Brain Metastases\nEstimated primary completion: January 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07623577
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06971406-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06971406)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Hig
 h-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed 
 in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeni
 ngeal Metastasis\nEstimated primary completion: 1 January 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06971406
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276100-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07276100)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Fecal Microbiota Transplantation
  to RESCUE Patients With Unresectable Hcc Progressors to First Line Therap
 y With AtezolizUmaB and Bevacizumab\nEstimated primary completion: 1 Janua
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0727
 6100
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05584670-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270120
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05584670)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: A First-in-human\, Dose Escala
 tion and Dose Expansion Study of SAR445877 in Adult Participants With Adva
 nced Solid Tumors\nEstimated primary completion: 19 January 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05584670
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03144167-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270120
DTEND;VALUE=DATE:20270121
SUMMARY:Bevacizumab: Phase na readout est. (NCT03144167)
DESCRIPTION:Bevacizumab\, phase na.\nStudy: Study of Prognostic Biomarkers 
 of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastoma
 s in First Relapse After Failure of Radiochemotherapy\nEstimated primary c
 ompletion: 20 January 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03144167
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059949-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07059949)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Short Course Radiotherapy Follow
 ed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial 
 Treatment of Unresectable Metastatic Rectal Cancer\nEstimated primary comp
 letion: 30 January 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07059949
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05096715-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT05096715)
DESCRIPTION:Bevacizumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: Atezo
 lizumab+Bevacizumab+SBRT in Unresectable HCC\nEstimated primary completion
 : 31 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/be
 vacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05096715
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06835179-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06835179)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: SBRT Combine
 d With CAPEOX\, Bevacizumab\, and PD-1 Inhibitor for the Treatment of RAS-
 Mutant\, MSS-Type\, Unresectable Metastatic Colorectal Cancer.\nEstimated 
 primary completion: February 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06835179
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229846-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07229846)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Single-arm
 \, Single-center\, Phase II Clinical Study of Aipalolitovorelizumab (QL170
 6) Combined With Bevacizumab and Standard Chemotherapy as First-line Treat
 ment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation\nE
 stimated primary completion: February 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07229846
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06801665-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06801665)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: FMT+ QL1706+
 Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorecta
 l Cancer With Liver Metastasis\nEstimated primary completion: 1 February 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06801665
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02884648-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT02884648)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Bevacizumab in 
 Ovarian Cancer Patients With Disease at Second-Look Surgery\nEstimated pri
 mary completion: 2 February 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT02884648
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05053750-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT05053750)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: TAME: A Pilot Study of Weekly Pa
 clitaxel\, Bevacizumab\, and Tumor Associated Macrophage Targeted Therapy 
 (Zoledronic Acid) in Women With Recurrent\, Platinum-resistant\, Epithelia
 l Ovarian\, Fallopian Tube or Primary Peritoneal Cancer\nEstimated primary
  completion: 2 February 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05053750
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06271837-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06271837)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: A Study of T-DXd as Monotherapy 
 or in Combination With Anti-cancer Agents in Patients With Selected HER2-e
 xpressing Tumors\nEstimated primary completion: 10 February 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06271837
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05377034-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05377034)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Multi
 national Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin
  Microspheres) Followed by Atezolizumab Plus Bevacizumab\, vs SIRT (SIRT-Y
 90) Followed by Placebo in Locally Advanced HCC Patients\nEstimated primar
 y completion: 15 February 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05377034
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01684397-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT01684397)
DESCRIPTION:Bevacizumab\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Pazopan
 ib Hydrochloride and Bevacizumab in Treating Patients With Previously Untr
 eated Metastatic Kidney Cancer\nEstimated primary completion: 20 February 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0168439
 7
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05062317-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05062317)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: ctDNA-Directed Post-Hepatectomy 
 Chemotherapy for Patients With Resectable Colorectal Liver Metastases\nEst
 imated primary completion: 28 February 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05062317
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 afety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Gli
 oblastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 
 28 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bev
 acizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06047379
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01837862-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT01837862)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: A Phase I Study of Mebendazole
  for the Treatment of Pediatric Gliomas\nEstimated primary completion: Mar
 ch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0183
 7862
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05141721-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT05141721)
DESCRIPTION:Bevacizumab\, phase 2/3\, Colorectal Cancer.\nStudy: A Study of
  a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoi
 nt Blockade for Patients With Metastatic Colorectal Cancer\nEstimated prim
 ary completion: March 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05141721
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05516628-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05516628)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Deep\
 , Multi-omics Phenotyping to Predict Response\, Resistance and Recurrence 
 to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carci
 noma\nEstimated primary completion: March 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05516628
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07246668-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07246668)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Pha
 se II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Car
 bon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy
  in Patients With Advanced Hepatocellular Carcinoma\nEstimated primary com
 pletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07246668
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05231122-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05231122)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Pembrolizumab C
 ombined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for th
 e Treatment of Patients With Recurrent Ovarian Cancer\nEstimated primary c
 ompletion: 15 March 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05231122
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06121401-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Bevacizumab: Phase 4 readout est. (NCT06121401)
DESCRIPTION:Bevacizumab\, phase 4.\nStudy: First Line Treatment With Olapar
 ib in Combination With Bevacizumab in HRD Positive Patients\nEstimated pri
 mary completion: 15 March 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06121401
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06899529-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270320
DTEND;VALUE=DATE:20270321
SUMMARY:Bevacizumab: Phase na readout est. (NCT06899529)
DESCRIPTION:Bevacizumab\, phase na.\nStudy: Immediate Postoperative Bevaciz
 umab Administration in Proliferative Diabetic Retinopathy Patients Undergo
 ing Vitrectomy\nEstimated primary completion: 20 March 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06899529
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04227028-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270325
DTEND;VALUE=DATE:20270326
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT04227028)
DESCRIPTION:Bevacizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Bri
 gatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanc
 ed\, Metastatic\, or Recurrent NSCLC\nEstimated primary completion: 25 Mar
 ch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0422
 7028
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06360042-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06360042)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Anti-
 PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment fo
 r Unresectable HCC\nEstimated primary completion: 31 March 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06360042
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06427941-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06427941)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase 1/2 Study of BGB-B2033\, Alone or in Combination With Tislelizumab 
 With or Without Bevacizumab\, in Participants With Advanced or Metastatic 
 Solid Tumors\nEstimated primary completion: 31 March 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06427941
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05445778-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05445778)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: Mirvetuximab So
 ravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-
 sensitive Epithelial Ovarian\, Fallopian Tube\, or Peritoneal Cancer\nEsti
 mated primary completion: April 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05445778
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07453394-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07453394)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Q
 LS5132 Combination Therapy in Advanced Solid Tumors\nEstimated primary com
 pletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07453394
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07560488-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07560488)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Ipili
 mumab N01 Combined With Sintilimab\, Bevacizumab Biosimilar\, and Hepatic 
 Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Inte
 rmediate-Advanced Hepatocellular Carcinoma\nEstimated primary completion: 
 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7560488
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05271240-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05271240)
DESCRIPTION:Bevacizumab\, phase 3.\nStudy: Repeated Superselective Intraart
 erial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radia
 tion Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM\n
 Estimated primary completion: 1 April 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05271240
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05919264-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05919264)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: FOG-001 in
  Locally Advanced or Metastatic Solid Tumors\nEstimated primary completion
 : 1 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevac
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05919264
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06876701-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06876701)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: The Treatment of Newly Diagnosed
  CD19+Mixed Phenotype Acute Leukemia in Adults\nEstimated primary completi
 on: 1 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bev
 acizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06876701
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06995105-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06995105)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Per
 sonalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcin
 oma\nEstimated primary completion: 1 April 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06995105
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06106308-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270416
DTEND;VALUE=DATE:20270417
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06106308)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Study of Onv
 ansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevaciz
 umab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Li
 ne Treatment of Metastatic Colorectal Cancer in Adult Participants With a 
 KRAS or NRAS Mutation\nEstimated primary completion: 16 April 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06106308
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06595108-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270425
DTEND;VALUE=DATE:20270426
SUMMARY:Bevacizumab: Phase na readout est. (NCT06595108)
DESCRIPTION:Bevacizumab\, phase na\, Hepatocellular Carcinoma.\nStudy: Atez
 olizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced 
 Hepatocellular Carcinoma\nEstimated primary completion: 25 April 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06595108
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05185505-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Bevacizumab: Phase 4 readout est. (NCT05185505)
DESCRIPTION:Bevacizumab\, phase 4\, Hepatocellular Carcinoma.\nStudy: Atezo
 lizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepato
 cellular Carcinoma Beyond Milan Criteria\nEstimated primary completion: 30
  April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05185505
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06397222-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06397222)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Sinti
 limab Plus Bevacizumab and SIRT for Intermediate-advanced HCC\nEstimated p
 rimary completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06397222
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742424-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06742424)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: PD-L1 Antibody + Bevacizumab Wit
 h Hepatic Arterial Infusion Chemotherapy for Advanced HCC\nEstimated prima
 ry completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06742424
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06799065-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06799065)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: F
 irst-in-Human Study of ATX-295\, an Oral Inhibitor of KIF18A\, as Monother
 apy and in Combination With Anticancer Therapy in Patients With Advanced o
 r Metastatic Solid Tumors\, Including Ovarian Cancer\nEstimated primary co
 mpletion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06799065
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06917092-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06917092)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: QL1706-Based Therapy Post-PD-1/L
 1 Failure in Advanced Endometrial Cancer\nEstimated primary completion: 30
  April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06917092
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03896074-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT03896074)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ate
 zolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Pati
 ents (BEAT)\nEstimated primary completion: May 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03896074
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06986785-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06986785)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Stu
 dy of BL-B01D1 Monotherapy\, BL-B01D1 in Combination With Lenvatinib\, BL-
 B01D1 in Combination With PD-1 Monoclonal Antibody\, and BL-B01D1 in Combi
 nation With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Adva
 nced Hepatocellular Carcinoma\nEstimated primary completion: May 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06986785
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07014215-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07014215)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: PD-
 1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced
  NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy\nEstimated primary
  completion: May 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07014215
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07054567-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07054567)
DESCRIPTION:Bevacizumab\, phase 2\, Cervical Cancer.\nStudy: A Study of BL-
 B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metasta
 tic Cervical Cancer and Endometrial Cancer\nEstimated primary completion: 
 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 54567
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06882915-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06882915)
DESCRIPTION:Bevacizumab\, phase 1\, Colorectal Cancer.\nStudy: Efficacy and
  Safety of Trifluridine/Tipiracil (TAS-102) Combined With Bevacizumab and 
 Serplulimab in Patients With Metastatic Colorectal Cancer Undergoing Cytor
 eductive Surgery: A Single-Arm\, Single-Center Clinical Study\nEstimated p
 rimary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06882915
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06420973-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06420973)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: RC48 Treatment 
 for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression\nEsti
 mated primary completion: 17 May 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06420973
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05440708-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270525
DTEND;VALUE=DATE:20270526
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05440708)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: A S
 tudy of TTI-101 as Monotherapy and in Combination in Participants With Loc
 ally Advanced or Metastatic\, and Unresectable Hepatocellular Carcinoma\nE
 stimated primary completion: 25 May 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05440708
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04721132-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT04721132)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Atezo
 lizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liv
 er Cancer\nEstimated primary completion: 31 May 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04721132
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06004245-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06004245)
DESCRIPTION:Bevacizumab\, phase 1\, Colorectal Cancer.\nStudy: A Study to E
 valuate the Safety\, Pharmacokinetics\, and Anti-Tumor Activity of VVD-133
 214 as Monotherapy and in Combination in Participants With Advanced Solid 
 Tumors\nEstimated primary completion: 31 May 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06004245
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07559760-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07559760)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: New Second-L
 ine Combo Therapy for MSS Metastatic Colorectal Cancer\nEstimated primary 
 completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07559760
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04999761-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT04999761)
DESCRIPTION:Bevacizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: AB1
 22 Platform Study\nEstimated primary completion: June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04999761
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06427239-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06427239)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: Exploratory Clinical Study of 
 HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic
  Ductal Adenocarcinoma\nEstimated primary completion: June 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06427239
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07244926-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07244926)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Sac
 -TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous N
 on-Small Cell Lung Cancer\nEstimated primary completion: June 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07244926
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653685-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07653685)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A Clinical
  Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevac
 izumab in Patients With HER2-Abnormally Expressed Unresectable Locally Adv
 anced or Metastatic Colorectal Cancer.\nEstimated primary completion: June
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076536
 85
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02997228-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT02997228)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: Testing the 
 Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone
  for Metastatic Colon or Rectal Cancer\, the COMMIT Study\nEstimated prima
 ry completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT02997228
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06557096-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06557096)
DESCRIPTION:Bevacizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: CSF
  CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-M
 utant Advanced NSCLC\nEstimated primary completion: 1 June 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06557096
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06576037-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06576037)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: Phase Ib Study of CBP-1019 in Co
 mbination With FOLFOX +/- Bevacizumab\, Pembrolizumab\, or Enzalutamide fo
 r Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin\nEstim
 ated primary completion: 1 June 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06576037
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07002346-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07002346)
DESCRIPTION:Bevacizumab\, phase 3.\nStudy: INVIGORATE: A Study of QL1706 an
 d Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma\nEstimat
 ed primary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07002346
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05627635-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270616
DTEND;VALUE=DATE:20270617
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05627635)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: FOLFOX and
  Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) 
 for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Can
 cer\nEstimated primary completion: 16 June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05627635
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06796907-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270621
DTEND;VALUE=DATE:20270622
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06796907)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: A Study of Mocertatug Rezeteca
 n in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEH
 OLD-2)\nEstimated primary completion: 21 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06796907
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Bevacizumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies 
 as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)\nEs
 timated primary completion: 30 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05112965-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05112965)
DESCRIPTION:Bevacizumab\, phase 3.\nStudy: An Extension Study in Participan
 ts Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Spon
 sored Atezolizumab Study (IMbrella C)\nEstimated primary completion: 30 Ju
 ne 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0511
 2965
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05405595-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05405595)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: ADG126 in Combination With Pem
 brolizumab in Patients With Advanced/Metastatic Solid Tumors\nEstimated pr
 imary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05405595
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05739981-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05739981)
DESCRIPTION:Bevacizumab\, phase 1/2\, Ovarian Cancer.\nStudy: Phase II IMNN
 -001 (Also Known as GEN-1) on SLL With BEV and NACT\, Newly Diagnosed Adva
 nced Ovarian\, Fallopian Tube or Primary Peritoneal Cancer\nEstimated prim
 ary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05739981
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06792695-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06792695)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Study of N
 ovel Study Interventions and Combinations in Participants With Colorectal 
 Cancer\nEstimated primary completion: 30 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06792695
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953843-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06953843)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy on the Optimal Combination Pattern of the Combined Treatment of Radioth
 erapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Can
 cer (NSCLC) With Multiple Metastases\nEstimated primary completion: 30 Jun
 e 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06953
 843
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07150247-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07150247)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Safety and E
 fficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer\nE
 stimated primary completion: 30 June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07150247
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07612137-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07612137)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: Study of IBI3005 Combination T
 herapy in Participants With Unresectable\, Locally Advanced or Metastatic 
 Solid Tumors\nEstimated primary completion: 30 June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07612137
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07870772-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07870772)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Lenva
 tinib Plus Bevacizumab and PD-1 Inhibition Versus Bevacizumab Plus PD-1 In
 hibition After Progression on Bevacizumab Plus Sintilimab in Unresectable 
 Hepatocellular Carcinoma: A Prospective\, Randomized\, Two-Cohort\, Phase 
 II Study\nEstimated primary completion: 30 June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07870772
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04803994-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT04803994)
DESCRIPTION:Bevacizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: The A
 BC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoemboliz
 ation (TACE) in Intermediate-stage HepatoCellular Carcinoma\nEstimated pri
 mary completion: July 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04803994
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05005403-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT05005403)
DESCRIPTION:Bevacizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy to Assess Adverse Events and Pharmacokinetics in Adult Participants Wit
 h Non-Small Cell Lung Cancer\, Head and Neck Squamous Cell Carcinoma and O
 ther Solid Tumors\, Receiving Intravenous Infusion of Azirkitug Alone or i
 n Combination(s) With Budigalimab\, Bevacizumab\, or Telisotuzumab Adizute
 can\nEstimated primary completion: July 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05005403
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07769853-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Bevacizumab: Phase na readout est. (NCT07769853)
DESCRIPTION:Bevacizumab\, phase na.\nStudy: Iparomlimab and Tuvonralimab Co
 mbined With Chemotherapy and Bevacizumab as Neoadjuvant Therapy for Locall
 y Advanced Rectal Cancer\nEstimated primary completion: 1 July 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07769853
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05238922-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270727
DTEND;VALUE=DATE:20270728
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT05238922)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: Study of INCB123667 in Subjects 
 With Advanced Solid Tumors\nEstimated primary completion: 27 July 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05238922
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04524871-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT04524871)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: A Study Evaluating the Efficac
 y and Safety of Multiple Immunotherapy-Based Treatment Combinations in Pat
 ients With Advanced Liver Cancers (Morpheus-Liver)\nEstimated primary comp
 letion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04524871
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06096779-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06096779)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Stu
 dy Evaluating Atezolizumab\, With or Without Bevacizumab\, in Participants
  With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrh
 osis\nEstimated primary completion: 30 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06096779
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03181100-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT03181100)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Atezolizumab With Chemotherapy i
 n Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cance
 r\nEstimated primary completion: 31 July 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03181100
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05797246-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05797246)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Bevacizumab in Adults With Recur
 rent Respiratory Papillomatosis (RRP)\nEstimated primary completion: 31 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0579
 7246
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05985798-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05985798)
DESCRIPTION:Bevacizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Sinti
 limab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC\nEstimated pri
 mary completion: 31 July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05985798
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07045805-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07045805)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Phase II Study of QL1706 Combine
 d With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Ga
 stric Cancer\nEstimated primary completion: 31 July 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07045805
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07106034-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07106034)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Standard Sec
 ond-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal C
 ancer: a Single-arm Phase II Trial\nEstimated primary completion: 31 July 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0710603
 4
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07138885-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07138885)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Pha
 se II\, Single-Arm\, Prospective Trial on the Efficacy and Safety of QL170
 6 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Re
 sistant Hepatocellular Carcinoma\nEstimated primary completion: 31 July 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07138885
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07714317-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07714317)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Pha
 se Ib/II Multicenter Randomized Control Study of Peri-operative Treatment 
 With Combination of CTLA-4\, PD-1 Antibodies and Bevacizumab in Resectable
  HCC (Prophet)\nEstimated primary completion: 31 July 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07714317
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01189643-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT01189643)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: Irinotecan\, Temozolomide and Be
 vacizumab in Combination With Existing High Dose Alkylator Based Chemother
 apy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Roun
 d Cell Tumor\nEstimated primary completion: August 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT01189643
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06695026-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06695026)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: A S
 tudy to Evaluate the Safety\, Tolerability and Efficacy of RZ-001 in Combi
 nation With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects
  With Hepatocellular Carcinoma\nEstimated primary completion: August 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06695026
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07080216-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07080216)
DESCRIPTION:Bevacizumab\, phase 1/2\, Cervical Cancer.\nStudy: Study of ZG0
 05 in Combination With Gecacitinib in Participants With Advanced Cervical 
 Cancer\nEstimated primary completion: August 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07080216
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05001880-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05001880)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Chemotherapy With or Without Imm
 unotherapy for Peritoneal Mesothelioma\nEstimated primary completion: 1 Au
 gust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 001880
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059494-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Bevacizumab: Phase 4 readout est. (NCT07059494)
DESCRIPTION:Bevacizumab\, phase 4\, Hepatocellular Carcinoma.\nStudy: Atezo
 lizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC 
 for Liver Transplant\nEstimated primary completion: 1 August 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07059494
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07085169-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07085169)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Low-dose Trifluridine/Tipiracil 
 With Bevacizumab in mCRC\nEstimated primary completion: 1 August 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07085169
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07733050-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07733050)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Efficacy and Safety of Serplulim
 ab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-L
 ine Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma\n
 Estimated primary completion: 1 August 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07733050
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446322-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07446322)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: FOLFIRI and 
 Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metast
 atic RAS-Mutated\, Microsatellite-Stable Colorectal Cancer\nEstimated prim
 ary completion: 30 August 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07446322
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04649489-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT04649489)
DESCRIPTION:Bevacizumab\, phase 3.\nStudy: A Study to Evaluate Efficacy and
  Safety of Hepatic Resection for Liver Cancer With PVTT\, HVTT or IVCTT Af
 ter Initial Ate/Bev\nEstimated primary completion: 31 August 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04649489
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06023862-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06023862)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: A Three-arm Randomized Phase II 
 Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemothe
 rapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENG
 OT-ov80 Study)\nEstimated primary completion: 31 August 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06023862
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07116577-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07116577)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Radiotherapy Combined QL1706\, T
 AS-102 and Bevacizumab in mCRC\nEstimated primary completion: 31 August 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07116577
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: The Drug Rediscovery Protocol (D
 RUP Trial)\nEstimated primary completion: September 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06084481-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06084481)
DESCRIPTION:Bevacizumab\, phase 1\, Ovarian Cancer.\nStudy: Study to Assess
  Adverse Events and Change in Disease Activity in Adult Participants With 
 Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-40
 0\nEstimated primary completion: September 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06084481
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06679985-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06679985)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Tri
 al of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Par
 ticipants With Unresectable and/or Locally Advanced or Metastatic Hepatoce
 llular Carcinoma\nEstimated primary completion: September 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06679985
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976671-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06976671)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: A Study to Determine the Safety 
 and Efficacy of Bevacizumab Administered Via Injection Into the Shoulder J
 oint of Participants With Adhesive Capsulitis (Frozen Shoulder)\nEstimated
  primary completion: September 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06976671
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07150208-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07150208)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: T-DXd With or Without Bevacizuma
 b for HER2-low Breast Cancer With Brain Metastasis\nEstimated primary comp
 letion: September 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07150208
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05976568-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT05976568)
DESCRIPTION:Bevacizumab\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: A S
 tudy of QL1706 in Combination With Bevacizumab and/or Chemotherapy as Firs
 t-line Treatment in Patients With Advanced Hepatocellular Carcinoma\nEstim
 ated primary completion: 1 September 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05976568
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788171-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06788171)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: PULSAR Combi
 ned With PD-1 Ab and Chemotherapy Plus Bev. for CRLM\nEstimated primary co
 mpletion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06788171
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07123441-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07123441)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Study on t
 he Efficacy and Safety of Irinotecan Liposome (II)\, 5-FU/LV in Combinatio
 n With Bevacizumab for the Treatment of Advanced Colorectal Cancer\nEstima
 ted primary completion: 1 September 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07123441
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07774247-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07774247)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Atezo
 lizumab\, Bevacizumab\, and Tocilizumab in Advanced Hepatocellular Carcino
 ma\nEstimated primary completion: 1 September 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07774247
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07819604-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07819604)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Serplulimab 
 Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Adv
 anced Colorectal Cancer\nEstimated primary completion: 1 September 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07819604
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05192798-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270910
DTEND;VALUE=DATE:20270911
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05192798)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Albumin-Bound Paclitaxel Combine
 d With Antiangiogenic Agents in First-line Treatment of Relapsed or Metast
 atic TNBC\nEstimated primary completion: 10 September 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05192798
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04837716-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270923
DTEND;VALUE=DATE:20270924
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT04837716)
DESCRIPTION:Bevacizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Ens
 artinib\, Carboplatin\, Pemetrexed and Bevacizumab for the Treatment of St
 age IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer\nEstim
 ated primary completion: 23 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04837716
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01061515-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270927
DTEND;VALUE=DATE:20270928
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT01061515)
DESCRIPTION:Bevacizumab\, phase 1\, Colorectal Cancer.\nStudy: Biweekly Int
 raperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Pa
 tients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cance
 r\nEstimated primary completion: 27 September 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT01061515
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06233942-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06233942)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: Phase 1a/1b First-in-Human Study
  of BG-C9074 Alone and in Combination With Other Anticancer Therapies in P
 atients With Advanced Solid Tumors\nEstimated primary completion: 28 Septe
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 233942
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03074513-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT03074513)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Atezolizumab and Bevacizumab in 
 Treating Patients With Rare Solid Tumors\nEstimated primary completion: 30
  September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/beva
 cizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT03074513
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05284643-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Bevacizumab: Phase na readout est. (NCT05284643)
DESCRIPTION:Bevacizumab\, phase na\, Recurrent Glioblastoma.\nStudy: Spectr
 oscopic MRI\, Proton Therapy\, and Avastin for Recurrent Glioblastoma\nEst
 imated primary completion: 30 September 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05284643
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06083844-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06083844)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Phase II Invest
 igation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclopho
 sphamide in Patients With High Grade Ovarian Cancer and Surgically Documen
 ted Minimal Residual Disease After Frontline Therapy\nEstimated primary co
 mpletion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06083844
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07474727-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07474727)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Phase II S
 tudy of AMT-676 Combination Therapies in Advanced Colorectal Cancer\nEstim
 ated primary completion: 30 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07474727
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134218-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT07134218)
DESCRIPTION:Bevacizumab\, phase 2/3.\nStudy: Neoadjuvant Chemoradiotherapy 
 Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Adva
 nced Rectal Cancer\nEstimated primary completion: October 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07134218
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134413-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07134413)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QL1
 706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC\nEstimated 
 primary completion: October 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07134413
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07478302-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT07478302)
DESCRIPTION:Bevacizumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: A Stu
 dy of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced He
 patocellular Carcinoma\nEstimated primary completion: October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07478302
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07497074-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07497074)
DESCRIPTION:Bevacizumab\, phase 2\, Cervical Cancer.\nStudy: JSKN033 Combin
 ation Therapy in Subjects With Advanced Cervical Cancer\nEstimated primary
  completion: October 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07497074
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897630-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07897630)
DESCRIPTION:Bevacizumab\, phase 3.\nStudy: Suprachoroidal Bevacizumab Versu
 s Intravitreal Bevacizumab in Diabetic Macular Edema\nEstimated primary co
 mpletion: October 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07897630
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05489211-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05489211)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Study of Dato-D
 Xd as Monotherapy and in Combination With Anti-cancer Agents in Patients W
 ith Advanced Solid Tumours (TROPION-PanTumor03)\nEstimated primary complet
 ion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05489211
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407465-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271020
DTEND;VALUE=DATE:20271021
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07407465)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Upfront Tras
 tuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER
 -2 Positive Metastatic Colorectal Cancer.\nEstimated primary completion: 2
 0 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevac
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07407465
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03141684-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT03141684)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Testing Atezolizumab Alone or At
 ezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sar
 coma\nEstimated primary completion: 31 October 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03141684
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06547385-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06547385)
DESCRIPTION:Bevacizumab\, phase 1\, Colorectal Cancer.\nStudy: Study of ONO
 -4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer\nEstimated pr
 imary completion: 31 October 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06547385
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05029882-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT05029882)
DESCRIPTION:Bevacizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy to Assess Adverse Events and Change in Disease Activity in Adult Partic
 ipants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as M
 onotherapy and in Combination With IV Bevacizumab\nEstimated primary compl
 etion: November 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05029882
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07239245-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271110
DTEND;VALUE=DATE:20271111
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07239245)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Study
  to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab
  Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
 \nEstimated primary completion: 10 November 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07239245
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318389-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271114
DTEND;VALUE=DATE:20271115
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT07318389)
DESCRIPTION:Bevacizumab\, phase 1\, Colorectal Cancer.\nStudy: ASCEND-CRC: 
 Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastat
 ic Colorectal Cancer\nEstimated primary completion: 14 November 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07318389
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933419-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271115
DTEND;VALUE=DATE:20271116
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07933419)
DESCRIPTION:Bevacizumab\, phase 1/2\, Ovarian Cancer.\nStudy: Phase Ib/II C
 linical Study of QLS5133 Combination Therapy in Advanced Solid Tumors\nEst
 imated primary completion: 15 November 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07933419
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265688-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06265688)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: First In Human Study of CX-2051 
 in Advanced Solid Tumors\nEstimated primary completion: 30 November 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06265688
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04250064-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT04250064)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: A Study of Low Dose Bevacizumab 
 With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma\n
 Estimated primary completion: December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04250064
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05112861-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05112861)
DESCRIPTION:Bevacizumab\, phase 3.\nStudy: A 3-month Study to Compare the S
 afety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visu
 al Impairment Due to Retinal Disorders\nEstimated primary completion: Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 112861
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05482893-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05482893)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: Spevatamig
  (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Thera
 py and/or ICI\, for the Treatment of Patients With Advanced Gastrointestin
 al Cancers\, Including Gastric\, Gastroesophageal Junction\, Pancreatic Du
 ctal or Biliary Tract Carcinomas (the TWINPEAK Study)\nEstimated primary c
 ompletion: December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05482893
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06303505-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06303505)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: F
 iH Study to Investigate Safety\, PK and Efficacy of the NaPi2b ADC TUB-040
  in Patients With PROC or r/r Adenocarcinoma NSCLC\nEstimated primary comp
 letion: December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06303505
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06906341-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06906341)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Relacorilant in
  Combination With Different Treatment Regimens in Patients With Gynecologi
 cal Cancers\nEstimated primary completion: December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06906341
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07179900-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07179900)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Radio
 therapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastat
 ic Hepatocellular Carcinoma\nEstimated primary completion: December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07179900
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07522411-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07522411)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Seq
 uential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy V
 ersus Direct Resection in Resectable High-Risk Recurrence Hepatocellular C
 arcinoma\nEstimated primary completion: December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07522411
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05733598-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05733598)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Study
  of RP2 in Combination With Second-line Therapy in Patients With Locally A
 dvanced or Metastatic HCC\nEstimated primary completion: 1 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05733598
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07347951-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07347951)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: A Single-center\, Phase II Study
  on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal
  Cancer\nEstimated primary completion: 1 December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07347951
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07670026-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07670026)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Intensified Adjuvant Therapy for
  High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-T
 erm Progression\nEstimated primary completion: 1 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07670026
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07909811-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT07909811)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: Novel endOvascular Therapy With 
 beVAcizumab and Cannabinoids for Glioblastoma\nEstimated primary completio
 n: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 evacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07909811
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03587311-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT03587311)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Bevacizumab and Anetumab Ravtans
 ine or Paclitaxel in Treating Patients With Refractory Ovarian\, Fallopian
  Tube\, or Primary Peritoneal Cancer\nEstimated primary completion: 15 Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 3587311
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05063552-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT05063552)
DESCRIPTION:Bevacizumab\, phase 2/3.\nStudy: Testing the Use of Investigati
 onal Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemot
 herapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancer
 s\nEstimated primary completion: 15 December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05063552
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06893887-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Bevacizumab: Phase na readout est. (NCT06893887)
DESCRIPTION:Bevacizumab\, phase na\, Hepatocellular Carcinoma.\nStudy: Indi
 vidualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma\n
 Estimated primary completion: 15 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06893887
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07042802-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271225
DTEND;VALUE=DATE:20271226
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07042802)
DESCRIPTION:Bevacizumab\, phase 1/2\, Ovarian Cancer.\nStudy: A Study of LB
 L-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of P
 latinum-resistant Ovarian Cancer\nEstimated primary completion: 25 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07042
 802
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07111546-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271226
DTEND;VALUE=DATE:20271227
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07111546)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: A Clinical Trial of LBL-024 Comb
 ination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
 \nEstimated primary completion: 26 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07111546
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06663306-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06663306)
DESCRIPTION:Bevacizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Int
 rathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomening
 eal Metastases in NSCLC\nEstimated primary completion: 30 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06663306
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07119931-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07119931)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Cli
 nical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Inj
 ection Plus Bevacizumab in Patients With Initially Potentially Resectable 
 Hepatocellular Carcinoma (ITBHaic Study)\nEstimated primary completion: 30
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevac
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07119931
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07197008-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07197008)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Sac
 ituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI
  Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis\nEst
 imated primary completion: 30 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07197008
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311577-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07311577)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Disitamab Vedot
 in Combined With Platinum and Bevacizumab as First-Line and Maintenance Th
 erapy for HER2-Expressing\, HRD-Negative High-Risk Ovarian Cancer: A Multi
 center\, Non-Randomized\, Single-Arm Phase II Clinical Study\nEstimated pr
 imary completion: 30 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07311577
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07314619-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07314619)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Prospective\, M
 ulticenter\, Single-Arm\, Phase Ⅱ Clinical Study on the Efficacy and Saf
 ety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resis
 tant Recurrent Ovarian Cancer\nEstimated primary completion: 30 December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07314619
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07327788-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07327788)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: QL170
 6 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcin
 oma With Vp3/4 PVTT\nEstimated primary completion: 30 December 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07327788
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07380633-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07380633)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Torip
 alimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE\, HA
 IC\, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2\, 
 Multicenter Randomised Non-comparative Trial\nEstimated primary completion
 : 30 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 evacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07380633
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07398599-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bevacizumab: Phase na readout est. (NCT07398599)
DESCRIPTION:Bevacizumab\, phase na\, Non-Small Cell Lung Cancer.\nStudy: Do
 uble-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemo
 therapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study\n
 Estimated primary completion: 30 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07398599
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416058-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07416058)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: PHO
 ENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant\, PD-L1 
 ≥50% Non-Squamous NSCLC\nEstimated primary completion: 30 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07416058
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503756-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07503756)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: JS212 Combin
 ation Therapies in Metastatic Colorectal Cancer\nEstimated primary complet
 ion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07503756
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07627347-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bevacizumab: Phase na readout est. (NCT07627347)
DESCRIPTION:Bevacizumab\, phase na.\nStudy: Efficacy and Safety of Anlotini
 b Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous
  Cell Carcinoma(ESCC)\nEstimated primary completion: 30 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07627347
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04449874-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT04449874)
DESCRIPTION:Bevacizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy to Evaluate the Safety\, Pharmacokinetics\, and Activity of GDC-6036 
 Alone or in Combination in Participants With Advanced or Metastatic Solid 
 Tumors With a KRAS G12C Mutation\nEstimated primary completion: 31 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04449
 874
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04566380-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT04566380)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: ONO-4538 Phase II Rollover Study
  (ONO-4538-98)\nEstimated primary completion: 31 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04566380
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04981509-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT04981509)
DESCRIPTION:Bevacizumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Testing o
 f Bevacizumab\, Erlotinib\, and Atezolizumab in Combination for Advanced-S
 tage Kidney Cancer\nEstimated primary completion: 31 December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04981509
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06478693-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06478693)
DESCRIPTION:Bevacizumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: A Stu
 dy of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers
 \, Including HCC\nEstimated primary completion: 31 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06478693
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06540261-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06540261)
DESCRIPTION:Bevacizumab\, phase 1\, Colorectal Cancer.\nStudy: The Study of
  ONO-7913\, ONO-4538 and the Standard of Care as First-line Treatment in P
 atients Colorectal Cancer\nEstimated primary completion: 31 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06540261
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06752382-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06752382)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Sintilimab Combined With Bevaciz
 umab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NP
 C\nEstimated primary completion: 31 December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06752382
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07448922-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07448922)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: A Study of SKB518 as Monotherapy
  or Combination Therapy in Patients With Advanced Gynecological Malignant 
 Tumors\nEstimated primary completion: 31 December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07448922
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07490262-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT07490262)
DESCRIPTION:Bevacizumab\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: A S
 tudy to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combinat
 ion Therapy in Patients With Hepatocellular Carcinoma as First-line Treatm
 ent.\nEstimated primary completion: 31 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07490262
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07562490-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07562490)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Randomized
  Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy
  Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer
 \nEstimated primary completion: 31 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07562490
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07750041-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07750041)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A Phase Ib
 /II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer\nEs
 timated primary completion: 31 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07750041
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563986-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06563986)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: FTD-TPI\, Be
 vacizumab\, and Radioembolization With 166Ho-microspheres in Refractory Me
 tastatic Colorectal Cancer\nEstimated primary completion: January 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06563986
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024784-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07024784)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: A Study to Asse
 ss Change in Disease Activity and Adverse Events in Adult Participants Wit
 h Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monothe
 rapy or in Combination With Other Therapies\nEstimated primary completion:
  January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaci
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07024784
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06771622-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06771622)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: Safety and Efficacy of HCB101 
 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
 \nEstimated primary completion: 1 January 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06771622
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07089719-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07089719)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Bevacizumab in Post-acute Sequel
 ae of COVID-19 : Efficacy and Safety (Pilot Study)\nEstimated primary comp
 letion: 1 January 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07089719
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06264531-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT06264531)
DESCRIPTION:Bevacizumab\, phase 2/3.\nStudy: Efficacy and Safety of Anti-an
 giogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral
  Arteriovenous Malformations\nEstimated primary completion: 15 January 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06264531
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06163820-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06163820)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: Bevacizumab and ICIs + hSRT in
  Symptomatic Melanoma Brain Metastases\nEstimated primary completion: 30 J
 anuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06163820
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06294548-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06294548)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: A S
 tudy of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab
  in HCC\nEstimated primary completion: 30 January 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06294548
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07128251-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07128251)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Sin
 gle-Arm\, Multicenter\, Exploratory Clinical Study of Transarterial Chemoe
 mbolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection an
 d Bevacizumab Injection for the Treatment of Unresectable\, Non-Metastatic
  Hepatocellular Carcinoma (HCC)\nEstimated primary completion: 30 January 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0712825
 1
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07355764-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07355764)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: MA-CRC-II-016 SHR-1811\nEstimate
 d primary completion: 30 January 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07355764
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01217931-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT01217931)
DESCRIPTION:Bevacizumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Sequentia
 l Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial\nE
 stimated primary completion: 31 January 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT01217931
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07941310-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07941310)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Phase 2 St
 udy of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal 
 Cancer\nEstimated primary completion: 31 January 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07941310
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04727307-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT04727307)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Neoad
 juvant Atezo\, Adjuvant Atezo + Beva Combined With RF Ablation of Small HC
 C: a Multicenter Randomized Phase II Trial\nEstimated primary completion: 
 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaci
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04727307
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07178717-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07178717)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Study to C
 haracterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V
 600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy W
 ith BRAF Inhibitors-based Combinations\nEstimated primary completion: Febr
 uary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 178717
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07470853-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT07470853)
DESCRIPTION:Bevacizumab\, phase 1\, Ovarian Cancer.\nStudy: A Study of MUC1
 6-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced S
 olid Tumors.\nEstimated primary completion: February 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07470853
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06728865-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06728865)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Eva
 luation of the Efficacy and Safety of Befotertinib Combined With Bevacizum
 ab as First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer Wi
 th Brain Metastases: A Single-Arm\, Open-Label\, Prospective Phase II Clin
 ical Study\nEstimated primary completion: 1 February 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06728865
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07337551-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07337551)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Gossypol Ace
 tate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive\nEstimat
 ed primary completion: 1 February 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07337551
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07277270-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280214
DTEND;VALUE=DATE:20280215
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT07277270)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: A Study of GSK5764227 in Combina
 tion With Standard of Care (SoC) or Other Agents in Participants With Adva
 nced Solid Tumors\nEstimated primary completion: 14 February 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07277270
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948448-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06948448)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Study to E
 valuate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo
 ®\, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care 
 in Participants With Non-MSI-H/dMMR\, PD-L1 Positive Advanced Colorectal C
 ancer\nEstimated primary completion: 15 February 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06948448
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439485-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280222
DTEND;VALUE=DATE:20280223
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06439485)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: Phase I/II Trial of Pemigatini
 b in Combination With Atezolizumab and Bevacizumab for Treatment of Advanc
 ed Cholangiocarcinoma With FGFR2 Fusion\nEstimated primary completion: 22 
 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaci
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06439485
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06663319-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280225
DTEND;VALUE=DATE:20280226
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06663319)
DESCRIPTION:Bevacizumab\, phase 1\, Colorectal Cancer.\nStudy: A Study of J
 NJ-89402638 for Metastatic Colorectal and Gastric Cancers\nEstimated prima
 ry completion: 25 February 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06663319
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04931342-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT04931342)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: A Study Evaluat
 ing the Efficacy and Safety of Biomarker-Driven Therapies in Patients With
  Persistent or Recurrent Rare Epithelial Ovarian Tumors\nEstimated primary
  completion: 28 February 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT04931342
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07070713-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07070713)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Efficacy and
  Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in 
 First-Line Treatment of Left-Sided mCRC\nEstimated primary completion: 28 
 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaci
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07070713
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05742425-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05742425)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Serplulimab Combined With FOLFIR
 I and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases\n
 Estimated primary completion: March 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05742425
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06820463-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06820463)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Study to E
 valuate the Adverse Events\, and Efficacy of Intravenous (IV) of Telisotuz
 umab Adizutecan in Combination With IV Oxaliplatin\, Fluorouracil\, Folini
 c Acid/Leucovorin\, Bevacizumab\, Panitumumab in Adult Participants With M
 etastatic Colorectal Cancer\nEstimated primary completion: March 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06820463
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07066657-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT07066657)
DESCRIPTION:Bevacizumab\, phase 1\, Colorectal Cancer.\nStudy: A Study of M
 RG007 (ARR-217) in Patients With Advanced Solid Tumors\nEstimated primary 
 completion: March 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07066657
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06642844-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280304
DTEND;VALUE=DATE:20280305
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT06642844)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: Bevacizumab-
 based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Tre
 atment\nEstimated primary completion: 4 March 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06642844
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05528952-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280327
DTEND;VALUE=DATE:20280328
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05528952)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Evalu
 ation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived 
 From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatoce
 llular Carcinoma\nEstimated primary completion: 27 March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05528952
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07518602-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280327
DTEND;VALUE=DATE:20280328
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07518602)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Efficacy and Safety of Chidamide
 +Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroend
 ocrine Carcinoma\nEstimated primary completion: 27 March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07518602
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05039801-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT05039801)
DESCRIPTION:Bevacizumab\, phase 1\, Ovarian Cancer.\nStudy: IACS-6274 With 
 or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid 
 Tumors\nEstimated primary completion: 30 March 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05039801
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07263438-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07263438)
DESCRIPTION:Bevacizumab\, phase 2\, Recurrent Glioblastoma.\nStudy: Efficac
 y of the Combination of Trimipramine and Atezolizumab With Bevacizumab in 
 Patients With Recurrent Glioblastoma: a Phase 2 Trial\nEstimated primary c
 ompletion: 30 March 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07263438
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776171-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07776171)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Trastuzumab Rez
 etecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemoth
 erapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer\nEstima
 ted primary completion: 30 March 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07776171
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07466238-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Bevacizumab: Phase na readout est. (NCT07466238)
DESCRIPTION:Bevacizumab\, phase na.\nStudy: HAIC Plus Systemic Therapy as D
 e-escalation Therapy Strategy for Biliary Tract Cancer\nEstimated primary 
 completion: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07466238
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07244705-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07244705)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A Study of
  ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Adva
 nced or mCRC\nEstimated primary completion: April 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07244705
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07479485-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07479485)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: MRG
 006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II
 )\nEstimated primary completion: April 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07479485
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07551778-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07551778)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
 llogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in 
 Advanced Solid Tumors\nEstimated primary completion: April 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07551778
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06733038-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT06733038)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: FOLFOXIRI Pl
 us Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR 
 and IS IC-High Metastatic Colorectal Cancer Patients.\nEstimated primary c
 ompletion: 1 April 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06733038
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07515625-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07515625)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Efficacy of Sintilimab Combined 
 With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gast
 ric/Gastroesophageal Junction Adenocarcinoma\nEstimated primary completion
 : 1 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevac
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07515625
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07642960-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Bevacizumab: Phase na readout est. (NCT07642960)
DESCRIPTION:Bevacizumab\, phase na.\nStudy: Fine-needle Diathermy Combined 
 With Subconjunctival Bevacizumab for Corneal Neovascularization\nEstimated
  primary completion: 1 April 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07642960
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07193862-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280415
DTEND;VALUE=DATE:20280416
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT07193862)
DESCRIPTION:Bevacizumab\, phase 1\, Colorectal Cancer.\nStudy: Pilot Study 
 of an Implantable Microdevice for In Situ Evaluation of Drug Response in P
 atients With Colorectal Liver Metastasis\nEstimated primary completion: 15
  April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07193862
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07009470-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Bevacizumab: Phase na readout est. (NCT07009470)
DESCRIPTION:Bevacizumab\, phase na\, Hepatocellular Carcinoma.\nStudy: A Mu
 lticenter\, Prospective Study of Perioperative Finotonlimab Combined With 
 Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk
  Factors for Recurrence\nEstimated primary completion: 28 April 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07009470
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01187199-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT01187199)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: Phase I Trial of Bevacizumab and
  Temsirolimus in Combination With 1) Carboplatin\, 2) Paclitaxel\, 3) Sora
 fenib for the Treatment of Advanced Cancer\nEstimated primary completion: 
 30 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaci
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT01187199
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04919629-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT04919629)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: APL-2 and Pembrolizumab Versus A
 PL-2\, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Trea
 tment of Recurrent Ovarian\, Fallopian Tube\, or Primary Peritoneal Cancer
  and Malignant Effusion\nEstimated primary completion: 30 April 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04919629
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06839105-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06839105)
DESCRIPTION:Bevacizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A C
 linical Study to Evaluate the Safety and Tolerability of AWT020 in Patient
 s With Advanced Malignancies\nEstimated primary completion: 30 April 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06839105
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06936527-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06936527)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: XS-03 in C
 ombination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metasta
 tic Colorectal Cancer Patients With RAS Mutation\nEstimated primary comple
 tion: 30 April 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06936527
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07714668-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07714668)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: A Clinical Stud
 y of SYS6041 Combination Therapy for Recurrent Ovarian Cancer\nEstimated p
 rimary completion: 30 April 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07714668
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07915921-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07915921)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A Phase Ib
 /II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or C
 etuximab in Patients With RAS-mutant Metastatic Colorectal Cancer\nEstimat
 ed primary completion: 30 April 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07915921
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01792934-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Bevacizumab: Phase na readout est. (NCT01792934)
DESCRIPTION:Bevacizumab\, phase na\, Colorectal Cancer.\nStudy: Chemotherap
 y and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases\
 nEstimated primary completion: May 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT01792934
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07824934-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT07824934)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: HEC-921 Injection as Monotherapy
  and in Combination With Antineoplastic Therapies in Patients With Advance
 d Malignant Solid Tumors\nEstimated primary completion: May 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07824934
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05101070-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05101070)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: S-531011 as Monotherapy and in
  Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic
  Solid Tumors\nEstimated primary completion: 31 May 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05101070
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06497985-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT06497985)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: A Study of T
 ucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Col
 orectal Cancer Patients\nEstimated primary completion: 31 May 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06497985
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07535632-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07535632)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: SBRT Followe
 d by PD-1 Inhibitor\, Bevacizumab and TAS-102 as Third-Line Therapy for Re
 current/Metastatic Colorectal Cancer\nEstimated primary completion: 1 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075356
 32
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06971744-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280618
DTEND;VALUE=DATE:20280619
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06971744)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Autophagy Maint
 enance (AUTOMAIN)\nEstimated primary completion: 18 June 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06971744
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03175432-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT03175432)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Bevacizumab and Atezolizumab Wit
 h or Without Cobimetinib in Treating Patients With Untreated Melanoma Brai
 n Metastases\nEstimated primary completion: 30 June 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03175432
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04516447-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT04516447)
DESCRIPTION:Bevacizumab\, phase 1\, Ovarian Cancer.\nStudy: A Study of Azen
 osertib (ZN-c3) in Patients With Ovarian Cancer\nEstimated primary complet
 ion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/be
 vacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04516447
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06737913-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06737913)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: HAI o
 r IV of Adebrelimab\, Combined With Bevacizumab and HAI of FOLFOX for Adva
 nced Unresectable Hepatocellular Carcinoma\nEstimated primary completion: 
 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaciz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06737913
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06787612-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06787612)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Investigation o
 f Ubamatamab Combination Therapy in Adult Participants With Platinum-Resis
 tant Ovarian Cancer\nEstimated primary completion: 30 June 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06787612
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07397819-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07397819)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: Intraperitoneal Injection of L
 iposomal Irinotecan as Monotherapy or in Combination With Recombinant Muta
 nt Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Maligna
 nt Ascites Following Failure of Prior Standard Therapy\nEstimated primary 
 completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07397819
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07638852-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07638852)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Study of Radiotherapy Combined W
 ith Cisplatin/Carboplatin\, Adebrelimab and Bevacizumab in the Treatment o
 f TNBC-BM.\nEstimated primary completion: 30 June 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07638852
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07774611-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07774611)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: An Open-label Study of SG1827 
 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Ad
 vanced Solid Tumors\nEstimated primary completion: 30 June 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07774611
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07841574-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07841574)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: HAIC Plus QL1706 & Bevacizumab i
 n Unresectable HER2-Negative ICC\nEstimated primary completion: 30 June 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07841574
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07893340-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07893340)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: First-line Treatment With Dual I
 mmunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Mal
 ignant Peritoneal Mesothelioma\nEstimated primary completion: 30 June 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07893340
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06031233-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Bevacizumab: Phase 4 readout est. (NCT06031233)
DESCRIPTION:Bevacizumab\, phase 4.\nStudy: Evaluating the Safety of Shorten
 ed Infusion Times for dIfferent Oncological Immunotherapie\nEstimated prim
 ary completion: July 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06031233
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268015-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06268015)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Botensilimab
  and Balstilimab Optimization in Colorectal Cancer\nEstimated primary comp
 letion: July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/be
 vacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06268015
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06701656-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06701656)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: JUST BREATHE\, Breathing Life In
 to Innovative Therapies for ARDS- Cohort C: Bevacizumab\nEstimated primary
  completion: July 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06701656
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06703073-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06703073)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: JUST BREATHE\, Breathing Life In
 to Innovative Therapies for ARDS (Master Record)\nEstimated primary comple
 tion: July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/beva
 cizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06703073
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06859762-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06859762)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: A First-in-Human Study of YL217 
 in Patients With Advanced Solid Tumors\nEstimated primary completion: July
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068597
 62
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06888817-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT06888817)
DESCRIPTION:Bevacizumab\, phase 3.\nStudy: Bevacizumab Versus Corticosteroi
 ds as First-line Treatment in Patients With Symptomatic Cerebral Radiation
  Necrosis After Radiation for High-grade Glioma or Brain Metastases\nEstim
 ated primary completion: July 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06888817
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07198074-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07198074)
DESCRIPTION:Bevacizumab\, phase 3.\nStudy: Testing the Addition of an Antia
 ngiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) 
 Combined With Immunotherapy (Pembrolizumab) for pMMR\, TP53 Mutated Endome
 trial Cancer\nEstimated primary completion: 1 July 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07198074
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619235-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Bevacizumab: Phase 4 readout est. (NCT07619235)
DESCRIPTION:Bevacizumab\, phase 4.\nStudy: A Single-arm\, Multicenter Clini
 cal Study of Iparomlimab and Toripalimab in Combination With Bevacizumab a
 nd Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer\
 nEstimated primary completion: 1 July 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07619235
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03768063-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280705
DTEND;VALUE=DATE:20280706
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT03768063)
DESCRIPTION:Bevacizumab\, phase 3.\nStudy: A Study in Patients Previously E
 nrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizu
 mab Study\nEstimated primary completion: 5 July 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03768063
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07062055-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280725
DTEND;VALUE=DATE:20280726
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07062055)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: BITS-
 TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT f
 or BCLC-C HCC With PVTT and/or Oligometastases\nEstimated primary completi
 on: 25 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bev
 acizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07062055
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07656038-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT07656038)
DESCRIPTION:Bevacizumab\, phase 1\, Colorectal Cancer.\nStudy: Nelmastobart
  in Combination With Tas-102 and Bevacizumab in Recurrent/Metastatic Color
 ectal Cancer\nEstimated primary completion: 31 July 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07656038
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722754-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07722754)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Bevacizumab\
 , Sintilimab\, Cetuximab and Irinotecan in Refractory RAS Wild-type Metast
 atic Colorectal Cancer: BOND-4 Trial\nEstimated primary completion: 31 Jul
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07722
 754
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06471465-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT06471465)
DESCRIPTION:Bevacizumab\, phase 3.\nStudy: Corticodependent or Corticoresis
 tant Brain Radionecrosis After Radiotherapy for Brain Metastases\nEstimate
 d primary completion: August 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06471465
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07681297-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07681297)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: Tislelizumab in Combination Wi
 th Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation i
 n Immunotherapy-Resistant and Central Nervous System Disease\nEstimated pr
 imary completion: August 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07681297
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06540729-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06540729)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: RC48 in Combination With AK104 a
 nd Bevacizumab in OCCC\nEstimated primary completion: 1 August 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06540729
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05797168-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280804
DTEND;VALUE=DATE:20280805
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05797168)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: P
 hase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Part
 icipants With Solid Tumors\nEstimated primary completion: 4 August 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05797168
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07420439-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07420439)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tre
 atment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interst
 itial Lung Disease\nEstimated primary completion: 15 August 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07420439
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06809946-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280817
DTEND;VALUE=DATE:20280818
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06809946)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Feasibility of Fluorescence Imag
 ing With Bevacizumab-800CW During Bronchoscopy\nEstimated primary completi
 on: 17 August 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 evacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06809946
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07074756-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Bevacizumab: Phase na readout est. (NCT07074756)
DESCRIPTION:Bevacizumab\, phase na\, Recurrent Glioblastoma.\nStudy: A Digi
 tal Treatment Platform for the Delivery of Home-Based Sequential Therapy i
 n Patients With Glioma\, GHoST Trial\nEstimated primary completion: 31 Aug
 ust 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 74756
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134101-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07134101)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Neoadjuvant 
 Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)\nEstimated pr
 imary completion: 31 August 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07134101
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07543510-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Bevacizumab: Phase na readout est. (NCT07543510)
DESCRIPTION:Bevacizumab\, phase na\, Hepatocellular Carcinoma.\nStudy: Low-
 Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable 
 Hepatocellular Carcinoma\nEstimated primary completion: 31 August 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07543510
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02885753-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT02885753)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: Systemic Oxa
 liplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinoteca
 n and an Target Therapy in First Line Treatment of Metastatic Colorectal C
 ancer Restricted to the Liver\nEstimated primary completion: September 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT02885753
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05854498-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05854498)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Liposomal Ir
 inotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorect
 al Cancer\nEstimated primary completion: September 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05854498
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07361991-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07361991)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: IBI363 Plus Bevacizumab With o
 r Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Can
 cer\nEstimated primary completion: September 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07361991
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07637851-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07637851)
DESCRIPTION:Bevacizumab\, phase 1/2\, Ovarian Cancer.\nStudy: Safety and Ef
 ficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer\nEstim
 ated primary completion: September 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07637851
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07670338-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Bevacizumab: Phase na readout est. (NCT07670338)
DESCRIPTION:Bevacizumab\, phase na.\nStudy: Xuan Yin Ning Plus Bevacizumab 
 for Malignant Pleural Effusion\nEstimated primary completion: 1 September 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0767033
 8
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07351487-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280925
DTEND;VALUE=DATE:20280926
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07351487)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Neoadjuvant Chemotherapy Combine
 d With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)\nEstimated 
 primary completion: 25 September 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07351487
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06133062-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06133062)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Atezo
 lizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatoce
 llular Carcinoma\nEstimated primary completion: 30 September 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06133062
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06445062-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06445062)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: Study of R
 AS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors\nEstimate
 d primary completion: 30 September 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06445062
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07328802-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07328802)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Exploration of Sintilimab + Beva
 cizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advance
 d/Metastatic Cholangiocarcinoma\nEstimated primary completion: 30 Septembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07328
 802
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07669610-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07669610)
DESCRIPTION:Bevacizumab\, phase 3.\nStudy: An Open-Label\, Randomized Phase
  III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First t
 o Third Line BLIS Subtype TNBC\nEstimated primary completion: 30 September
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076696
 10
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07817888-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07817888)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: mFOLFOXIRI Plus Bevacizumab for 
 Organ Preservation in Locally Advanced Rectal Cancer\nEstimated primary co
 mpletion: 30 September 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07817888
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843303-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07843303)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Trastuzumab Rez
 etecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer\nEs
 timated primary completion: 30 September 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07843303
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01269853-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT01269853)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: Repeated Super-selective Intra
 arterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relap
 sed GBM and AA\nEstimated primary completion: October 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT01269853
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772882-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT07772882)
DESCRIPTION:Bevacizumab\, phase 1\, Ovarian Cancer.\nStudy: Study of Supple
 mental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant 
 Ovarian\, Fallopian Tube\, and Peritoneal Cancer\nEstimated primary comple
 tion: October 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 evacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07772882
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288034-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281008
DTEND;VALUE=DATE:20281009
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07288034)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Imm
 unotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Res
 ponse and Selection of Second-line Treatment in Stage IIIB-IV Non-small Ce
 ll Lung Cancer\, IMMUNO-BIOMAP Trial\nEstimated primary completion: 8 Octo
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072
 88034
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07833735-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281015
DTEND;VALUE=DATE:20281016
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07833735)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: A Study to Evaluate the Safety
 \, Tolerability\, Pharmacokinetic Profile\, and Preliminary Efficacy of SY
 S6043 ± Bevacizumab ± Chemotherapy in Participants With Advanced Solid T
 umors\nEstimated primary completion: 15 October 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07833735
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06551142-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281016
DTEND;VALUE=DATE:20281017
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06551142)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: A Study of GSK5764227 in Partici
 pants With Advanced Solid Tumors (EMBOLD)\nEstimated primary completion: 1
 6 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevac
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06551142
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06789757-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281027
DTEND;VALUE=DATE:20281028
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06789757)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: The S
 tudy of Atezolizumab\, Bevacizumab and Memantine in Patients With Hepatoce
 llular Carcinoma (HCC)\nEstimated primary completion: 27 October 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06789757
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722494-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07722494)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: IBI363 Combi
 ned With Bevacizumab for Advanced Colorectal Cancer\nEstimated primary com
 pletion: 31 October 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07722494
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06625775-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06625775)
DESCRIPTION:Bevacizumab\, phase 1\, Colorectal Cancer.\nStudy: Open-Label S
 tudy of BBO-10203 in Subjects With Advanced Solid Tumors\nEstimated primar
 y completion: November 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06625775
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07075757-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT07075757)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: In Situ Injection of Anti-angiog
 enics in Patients With Brain Arteriovenous Malformations Not Eligible for 
 Exclusion Treatment\nEstimated primary completion: 1 November 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07075757
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07547592-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07547592)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Gemcitabine and Docetaxel With o
 r Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma\nEstimated primary
  completion: 30 November 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07547592
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03351296-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT03351296)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Two Chemotherapy Regimens Plus o
 r Minus Bevacizumab\nEstimated primary completion: December 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT03351296
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03715933-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT03715933)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: Phase 1 Study of INBRX-109 in Su
 bjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
 \nEstimated primary completion: December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03715933
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04121455-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT04121455)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: Glioblastoma Treatment With Ir
 radiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients\nEst
 imated primary completion: December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04121455
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05009082-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05009082)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: Niraparib vs Ni
 raparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemothera
 py in Advanced Ovarian Cancer\nEstimated primary completion: December 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05009082
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05579366-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05579366)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: R
 inatabart Sesutecan (Rina-S\, PRO1184\, GEN1184) for Advanced Solid Tumors
  (GCT1184-01/ PRO1184-001)\nEstimated primary completion: December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05579366
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06680258-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT06680258)
DESCRIPTION:Bevacizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: A Stu
 dy of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unrese
 ctable or Metastatic HCC Not Previously Treated With Systemic Therapy\nEst
 imated primary completion: December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06680258
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06878196-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase na readout est. (NCT06878196)
DESCRIPTION:Bevacizumab\, phase na\, Cervical Cancer.\nStudy: ctDNA-guided 
 First-line Immuno-de-escalation Therapy for IVB-stage and Recurrent Cervic
 al Cancer\nEstimated primary completion: December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06878196
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06895928-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06895928)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: A Trial of SHR-A2102 With Other 
 Antitumor Therapies in Advanced Solid Tumors\nEstimated primary completion
 : December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/beva
 cizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06895928
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071844-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07071844)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: BETWEEN: Biw
 eekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia
  in mCRC Patients\nEstimated primary completion: December 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07071844
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07278336-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT07278336)
DESCRIPTION:Bevacizumab\, phase 1\, Ovarian Cancer.\nStudy: A Study to Asse
 ss Adverse Events\, Change in Disease Activity and How Intravenous (IV) AB
 BV901 Moves Through the Body Alone or in Combination With Other Anticancer
  Drugs in Adult Participants With Ovarian Cancer\nEstimated primary comple
 tion: December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07278336
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527858-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07527858)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Study of Den
 ikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adu
 lts With Advanced Colorectal Cancer\nEstimated primary completion: Decembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07527
 858
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07557251-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT07557251)
DESCRIPTION:Bevacizumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: A Stu
 dy to Evaluate the Safety\, Tolerability\, and Preliminary Efficacy of BRI
 I-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatiti
 s B Virus Related Hepatocellular Carcinoma\nEstimated primary completion: 
 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaci
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07557251
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07737600-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07737600)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A Study of
  MRG007 Combination Therapy for Advanced Colorectal Cancer\nEstimated prim
 ary completion: December 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07737600
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07274787-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Bevacizumab: Phase na readout est. (NCT07274787)
DESCRIPTION:Bevacizumab\, phase na\, Recurrent Glioblastoma.\nStudy: Safety
  And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Gliobla
 stoma\nEstimated primary completion: 1 December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07274787
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07331883-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07331883)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Sinti
 limab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Res
 ection of Ruptured Hepatocellular Carcinoma (CLEAR-2)\nEstimated primary c
 ompletion: 1 December 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07331883
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07317414-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281205
DTEND;VALUE=DATE:20281206
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07317414)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: β-al
 anine in the Treatment of Advanced Hepatocellular Carcinoma\nEstimated pri
 mary completion: 5 December 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07317414
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05769010-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05769010)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Study of SHR-A1811 in HER2-expre
 ssion Advanced Breast Cancer With Brain Metastases\nEstimated primary comp
 letion: 30 December 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05769010
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492408-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06492408)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Neoad
 juvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.\nEst
 imated primary completion: 30 December 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06492408
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492421-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06492421)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neo
 adjuvant Intra-tumor Double Immunotherapy for Lung Cancer.\nEstimated prim
 ary completion: 30 December 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06492421
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07058428-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07058428)
DESCRIPTION:Bevacizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: FSR
 T Combines With Bevacizumab for Multiple Brain Metastases in Lung Adenocar
 cinoma\nEstimated primary completion: 30 December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07058428
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07729605-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07729605)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: FOLFIRI Plus
  Bevacizuamb and QL1706 in Second-Line Treatment for mCRC\nEstimated prima
 ry completion: 30 December 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07729605
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895992-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07895992)
DESCRIPTION:Bevacizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: SHR
 -A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or M
 etastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlle
 d\, Open\, Multicenter Phase III Study\nEstimated primary completion: 30 D
 ecember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaciz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07895992
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04017455-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT04017455)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Neoadjuvant Treatment in Rectal 
 Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)
 \nEstimated primary completion: 31 December 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04017455
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05441475-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05441475)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Pha
 se 2\, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Pa
 tients\nEstimated primary completion: 31 December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05441475
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07004335-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 4 readout est. (NCT07004335)
DESCRIPTION:Bevacizumab\, phase 4.\nStudy: Efficacy and Safety of Iparomlim
 ab and Tuvonralimab Injection in Combination With Bevacizumab After Progre
 ssion on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective\, Single
 -Arm\, Exploratory Clinical Study\nEstimated primary completion: 31 Decemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0700
 4335
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07035808-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07035808)
DESCRIPTION:Bevacizumab\, phase 2\, Cervical Cancer.\nStudy: a Single Arm\,
  Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety o
 f the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherap
 y ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherap
 y in Patients With Advanced Cervical Cancer .\nEstimated primary completio
 n: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07035808
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281664-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase na readout est. (NCT07281664)
DESCRIPTION:Bevacizumab\, phase na\, Hepatocellular Carcinoma.\nStudy: Tran
 sarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as
  First-Line Treatment for Unresectable Hepatocellular Carcinoma\nEstimated
  primary completion: 31 December 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07281664
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391566-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07391566)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: LPM6690176
  in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal
  Cancer Patients With RAS Mutation\nEstimated primary completion: 31 Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073
 91566
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07678684-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07678684)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: A Study of HF1K16 Combined With 
 Bevacizumab in Patients With Recurrent or Progressive Glioma\nEstimated pr
 imary completion: 31 December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07678684
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05363722-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT05363722)
DESCRIPTION:Bevacizumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: Clini
 cal Study on Efficacy and Safety of IBI310\, Bevacizumab Combined With Sin
 tilimab in Advanced HCC\nEstimated primary completion: January 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05363722
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059845-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07059845)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: A Study to Asse
 ss Adverse Events and Change in Disease Activity of Multiple Treatment Com
 binations With Intravenous Mirvetuximab Soravtansine in Adult Participants
  With Ovarian Cancer\nEstimated primary completion: January 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07059845
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07324824-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07324824)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Sinti
 limab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable He
 patocellular Carcinoma\nEstimated primary completion: January 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07324824
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07729098-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT07729098)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: Intra-Arterial Bevacizumab as an
  Adjunct to Middle Meningeal Artery Embolization for Chronic Subdural Hema
 toma\nEstimated primary completion: 1 January 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07729098
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900165-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07900165)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: Study of V
 arsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorecta
 l Cancer\nEstimated primary completion: February 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07900165
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04712643-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT04712643)
DESCRIPTION:Bevacizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: A Stu
 dy of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Pa
 tients With Untreated Heaptocellular Carcionma\nEstimated primary completi
 on: 1 February 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04712643
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07395063-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07395063)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Clinical S
 tudy on the Treatment of Metastatic Colorectal Cancer at the Second-line o
 r Beyond.\nEstimated primary completion: 1 February 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07395063
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07904845-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290227
DTEND;VALUE=DATE:20290228
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT07904845)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: A Study of BON-C1393 in Adults W
 ith Advanced Solid Tumors\nEstimated primary completion: 27 February 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07904845
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472647-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07472647)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 YS6090 Combination Therapy in Advanced Lung Cancer\nEstimated primary comp
 letion: 28 February 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07472647
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07661173-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290306
DTEND;VALUE=DATE:20290307
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07661173)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 rospective Study of Firmonertinib as First-line Adaptive Therapy Guided by
  Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutate
 d Non-small Cell Lung Cancer\nEstimated primary completion: 6 March 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07661173
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06843447-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290327
DTEND;VALUE=DATE:20290328
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06843447)
DESCRIPTION:Bevacizumab\, phase 1/2\, Ovarian Cancer.\nStudy: A Clinical St
 udy of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
 \nEstimated primary completion: 27 March 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06843447
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06339424-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06339424)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Atezo
 lizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatoce
 llular Carcinoma\nEstimated primary completion: 30 March 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06339424
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06823375-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06823375)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: SBRT With Immunotherapy and Atez
 o-Bev in HCC With Major Portal Vein Thrombosis\nEstimated primary completi
 on: 31 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/be
 vacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06823375
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010497-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07010497)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Pro
 spective Study to Evaluate the Safety and Efficacy of the Combination Ther
 apy of Irpagratinib\, Atezolizumab\, and Bevacizumab in Patients With Hepa
 tocellular Carcinoma\nEstimated primary completion: 31 March 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07010497
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514793-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07514793)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Iparomlimab Plus Tovorilimab Com
 bined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanc
 ed Mesothelioma\nEstimated primary completion: April 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07514793
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07663513-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07663513)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Iparomlimab and
  Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadj
 uvant Therapy for Advanced Ovarian Cancer\nEstimated primary completion: A
 pril 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 663513
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797244-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07797244)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Single-Arm
 \, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevaci
 zumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Canc
 er With Liver Metastases (CRLM)\nEstimated primary completion: April 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07797244
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07504588-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290412
DTEND;VALUE=DATE:20290413
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07504588)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Sacituzumab Gov
 itecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin\, Pegy
 lated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platin
 um-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy\nEsti
 mated primary completion: 12 April 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07504588
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318805-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290414
DTEND;VALUE=DATE:20290415
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT07318805)
DESCRIPTION:Bevacizumab\, phase 1\, Colorectal Cancer.\nStudy: A Study to L
 earn About the Study Medicine Called PF-08032562 in People With Advanced o
 r Metastatic Solid Tumors\nEstimated primary completion: 14 April 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07318805
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07549399-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07549399)
DESCRIPTION:Bevacizumab\, phase 3.\nStudy: SCRT + Chemo Targeted Immuno-neo
 adjuvant Therapy for High-risk pMMR/MSS RC\nEstimated primary completion: 
 30 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaci
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07549399
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07525206-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07525206)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: A Study to A
 ccess Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bev
 acizumab Compared to Standard of Care IV Bevacizumabin Combination With Or
 al Trifluridine and Tipiracil in Adult Participants With Refractory Metast
 atic Colorectal Cancer\nEstimated primary completion: May 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07525206
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05836324-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290503
DTEND;VALUE=DATE:20290504
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT05836324)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: A Study to Evaluate the Safety o
 f INCA33890 in Participants With Advanced or Metastatic Solid Tumors\nEsti
 mated primary completion: 3 May 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05836324
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07863869-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290527
DTEND;VALUE=DATE:20290528
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07863869)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: The QL1706
  Combined With Chemotherapy and Either Cetuximab or Bevacizumab in Potenti
 ally Resectable Colorectal Cancer Patients With Liver Metastases\nEstimate
 d primary completion: 27 May 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07863869
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06400472-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06400472)
DESCRIPTION:Bevacizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Sofe-M in Participants With Selected Advanced Solid Tumors\nEstima
 ted primary completion: June 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06400472
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07541781-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290611
DTEND;VALUE=DATE:20290612
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT07541781)
DESCRIPTION:Bevacizumab\, phase 1\, Recurrent Glioblastoma.\nStudy: Sitagli
 ptin in Recurrent/Progressive Grade 4 Glioma\nEstimated primary completion
 : 11 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevac
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07541781
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07674732-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290624
DTEND;VALUE=DATE:20290625
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07674732)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Nodal-Region Sparing Short-Cours
 e RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as 
 TNT in pMMR/MSS Locally Advanced Rectal Cancer\nEstimated primary completi
 on: 24 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bev
 acizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07674732
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04181060-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT04181060)
DESCRIPTION:Bevacizumab\, phase 3.\nStudy: Osimertinib With or Without Beva
 cizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer\nEs
 timated primary completion: 30 June 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04181060
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06605664-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06605664)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Hyper
 polarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Rad
 iotherapy\, Atezolizumab\, and Bevacizumab\nEstimated primary completion: 
 30 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaciz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06605664
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953323-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06953323)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: A Phase I/II Study of WJB001 C
 ombination Therapy on Safety and Efficacy for Advanced Solid Tumors\nEstim
 ated primary completion: 30 June 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06953323
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07728019-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07728019)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Efficacy and
  Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or With
 out Short-Course Radiotherapy in Patients With CRCLM\nEstimated primary co
 mpletion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07728019
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07235930-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07235930)
DESCRIPTION:Bevacizumab\, phase 3.\nStudy: Firstline Sequential AG and mFOL
 FOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone
  in Advanced Pancreatic Cancer\nEstimated primary completion: 1 July 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07235930
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07756840-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07756840)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Combination Bevacizumab and PRGN
 -2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)\nEstimated
  primary completion: 1 July 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07756840
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07870733-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Bevacizumab: Phase na readout est. (NCT07870733)
DESCRIPTION:Bevacizumab\, phase na\, Non-Small Cell Lung Cancer.\nStudy: Ne
 oadjuvant Iruplinalkib and Bevacizumab in ALK-positive NSCLC: A Phase II S
 ingle-arm Trial\nEstimated primary completion: 1 July 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07870733
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05203172-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Bevacizumab: Phase 4 readout est. (NCT05203172)
DESCRIPTION:Bevacizumab\, phase 4.\nStudy: The FLOTILLA Study: Providing Co
 ntinued Access to The Study Medicines Encorafenib and Binimetinib for Part
 icipants in Prior Clinical Trials\nEstimated primary completion: 31 July 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05203172
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03899155-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290825
DTEND;VALUE=DATE:20290826
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT03899155)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Pan Tumor Rollover Study\nEstima
 ted primary completion: 25 August 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03899155
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07543783-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07543783)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Effic
 acy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Tran
 sarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemothe
 rapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular C
 arcinoma: A Single-arm Phase 2 Trial\nEstimated primary completion: 31 Aug
 ust 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075
 43783
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04188145-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT04188145)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: A Randomized
  Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + B
 evacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Meta
 static Colorectal Cancer\nEstimated primary completion: September 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04188145
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976944-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06976944)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Pembrolizumab + Paclitaxel +/- B
 evacizumab for Triple-negative Breast Cancer\nEstimated primary completion
 : September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bev
 acizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06976944
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07676162-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07676162)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: A Clinical S
 tudy of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus 
 Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer\nE
 stimated primary completion: September 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07676162
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07828015-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07828015)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Bevacizumab in the Treatment of 
 HHT\nEstimated primary completion: 1 September 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07828015
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06131840-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290912
DTEND;VALUE=DATE:20290913
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06131840)
DESCRIPTION:Bevacizumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of SGN-CEACAM5C in Adults With Advanced Solid Tumors\nEstimated prima
 ry completion: 12 September 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06131840
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07481786-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290915
DTEND;VALUE=DATE:20290916
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07481786)
DESCRIPTION:Bevacizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Bev
 acizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma
  With Extensive Brain Metastases\nEstimated primary completion: 15 Septemb
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0748
 1786
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07761286-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07761286)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Eva
 luate the Safety and Efficacy of Combination Therapy With SYS6090 Injectio
 n for Hepatocellular Carcinoma\nEstimated primary completion: 30 September
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077612
 86
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04587128-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT04587128)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Early-Line A
 nti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC\n
 Estimated primary completion: October 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04587128
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07847671-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07847671)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Fecal
  Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Adva
 nced HCC\nEstimated primary completion: October 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07847671
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05956821-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05956821)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: Treatment of Relapsed/Refracto
 ry Intracranial Glioma in Patients Under 22 Years of Age\nEstimated primar
 y completion: 1 October 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05956821
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07835737-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07835737)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Saf
 ety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab 
 as First-Line Therapy for Unresectable Hepatocellular Carcinoma\nEstimated
  primary completion: 1 October 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07835737
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07549412-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20291016
DTEND;VALUE=DATE:20291017
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07549412)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: A Study of P
 recemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridin
 e/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metas
 tatic Colorectal Cancer (PROCEADE-CRC-03)\nEstimated primary completion: 1
 6 October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevac
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07549412
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05462613-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT05462613)
DESCRIPTION:Bevacizumab\, phase 2/3\, Colorectal Cancer.\nStudy: Regorafeni
 b With Low-dose Chemotherapies and Aspirin Followed by Standard Chemothera
 pies in Metastatic Colorectal Cancer\nEstimated primary completion: Novemb
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0546
 2613
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621497-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07621497)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: FOLFOX8 Vers
 us mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Meta
 static Colorectal Cancer (Phase II)\nEstimated primary completion: 1 Novem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 21497
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564141-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07564141)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: Study to Assess
  the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to
  Investigator's Choice of Platinum-based Chemotherapy With or Without Beva
 cizumab as Second-line Treatment in Participants With Recurrent Platinum-s
 ensitive Ovarian Cancer\nEstimated primary completion: December 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07564141
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04374305-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT04374305)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Innovative Trial for Understandi
 ng the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUIT
 T-NF2)\nEstimated primary completion: 1 December 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04374305
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07926477-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07926477)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: Trastuzumab 
 Rezetecan + Bevacizumab vs. TAS-102 + Bevacizumab in Pretreated mCRC With 
 HER2 Low/Moderate Expression or HER2 Positivity With RAS/BRAF Mutation\nEs
 timated primary completion: 1 December 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07926477
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07182708-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07182708)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Hig
 h-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectabl
 e EGFRm Stage II-IIIB NSCLC\nEstimated primary completion: 30 December 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07182708
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07821606-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07821606)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: Phase III Study
  of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Canc
 er\nEstimated primary completion: 30 December 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07821606
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03872661-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT03872661)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neo
 adjuvant IBI308\, Bevacizumab\, Plus Pemetrexed and Carboplatin Followed b
 y Surgery in Unresectable Stage III NSCLC\nEstimated primary completion: 3
 1 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/beva
 cizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT03872661
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06061809-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06061809)
DESCRIPTION:Bevacizumab\, phase 2\, Recurrent Glioblastoma.\nStudy: N-803 a
 nd PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Gli
 oblastoma\nEstimated primary completion: 31 December 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06061809
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07283367-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07283367)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A Phase Ib
 /II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer 
 Patients.\nEstimated primary completion: 31 December 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07283367
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07370818-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07370818)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: To Evaluate the
  Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Mainten
 ance Therapy in Relapsed Ovarian Cancer\nEstimated primary completion: 31 
 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaci
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07370818
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07383285-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07383285)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: CAPOX and Bevacizumab With or Wi
 thout Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First
 -line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer\nEstimated pri
 mary completion: 31 December 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07383285
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06254248-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06254248)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Safet
 y of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced
  Hepatocellular Carcinoma\nEstimated primary completion: 1 January 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06254248
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890338-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06890338)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: A Study to Asse
 ss Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirv
 etuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor
  Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian\, Fallopi
 an Tube or Primary Peritoneal Cancer.\nEstimated primary completion: Febru
 ary 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068
 90338
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221357-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300202
DTEND;VALUE=DATE:20300203
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT07221357)
DESCRIPTION:Bevacizumab\, phase 2/3\, Colorectal Cancer.\nStudy: A Study to
  Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemoth
 erapy Versus Bevacizumab in Combination With Chemotherapy in Participants 
 With Previously Untreated\, Unresectable\, or Metastatic Colorectal Cancer
 \nEstimated primary completion: 2 February 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07221357
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07779538-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07779538)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: Clinical Trials
  Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Mai
 ntenance Therapy for Epithelial Ovarian Cancer\nEstimated primary completi
 on: 28 February 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07779538
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392866-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300301
DTEND;VALUE=DATE:20300302
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT07392866)
DESCRIPTION:Bevacizumab\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: A C
 linical Study of SH006 Injection in Combination Therapy Versus Regorafenib
  in the Treatment of Advanced Hepatocellular Carcinoma\nEstimated primary 
 completion: 1 March 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07392866
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07183865-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300309
DTEND;VALUE=DATE:20300310
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07183865)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Hypofractionated Radiotherapy Co
 mbined With NALIRIF\, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOV
 ELTY-R)\nEstimated primary completion: 9 March 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07183865
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06928584-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300310
DTEND;VALUE=DATE:20300311
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06928584)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Hypofractionated Radiotherapy Pl
 us Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rec
 tal Cancer\nEstimated primary completion: 10 March 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06928584
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06921785-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300315
DTEND;VALUE=DATE:20300316
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT06921785)
DESCRIPTION:Bevacizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Phase
  III Study of Rilvegostomig in Combination With Bevacizumab With or Withou
 t Tremelimumab as First-line Treatment of Hepatocellular Carcinoma\nEstima
 ted primary completion: 15 March 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06921785
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01356290-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT01356290)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Antiangiogenic Therapy for Child
 ren With Recurrent Medulloblastoma\, Ependymoma\, ATRT and Rare CNS Tumors
 \nEstimated primary completion: April 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT01356290
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05797467-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05797467)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: Adjuvant Che
 motherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal C
 ancer Patients\nEstimated primary completion: 1 April 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05797467
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05719558-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT05719558)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: A Study of ASP1002 in Adults for
  Treatment of Solid Tumors\nEstimated primary completion: 30 April 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05719558
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07645625-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Bevacizumab: Phase 4 readout est. (NCT07645625)
DESCRIPTION:Bevacizumab\, phase 4\, Cervical Cancer.\nStudy: Pembrolizumab 
 Registry for Outcomes and Treatment Evaluation in Cervical Cancer\nEstimat
 ed primary completion: May 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07645625
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06954584-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300501
DTEND;VALUE=DATE:20300502
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT06954584)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: Fluzoparib+Beva
 cizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maint
 enance in HRD+/- Advanced Ovarian Cancer\nEstimated primary completion: 1 
 May 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 54584
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07854964-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300515
DTEND;VALUE=DATE:20300516
SUMMARY:Bevacizumab: Phase na readout est. (NCT07854964)
DESCRIPTION:Bevacizumab\, phase na.\nStudy: A Prospective\, Single-center\,
  Phase II Study of Neoadjuvant Serplulimab Plus XELOX and Bevacizumab in L
 ocally Advanced Rectal Cancer\nEstimated primary completion: 15 May 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07854964
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684612-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300521
DTEND;VALUE=DATE:20300522
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07684612)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: A Study to Inve
 stigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doubl
 et With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer
  (BEHOLD-Ovarian02)\nEstimated primary completion: 21 May 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07684612
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06469281-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300527
DTEND;VALUE=DATE:20300528
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT06469281)
DESCRIPTION:Bevacizumab\, phase 1\, Ovarian Cancer.\nStudy: A Study to Lear
 n if 27T51\, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy\, Ad
 ministered Alone or in Combination is Safe and How Well it Works for Adult
  Participants With Recurrent or Treatment Resistant Ovarian Cancers\nEstim
 ated primary completion: 27 May 2030. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06469281
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594340-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300530
DTEND;VALUE=DATE:20300531
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07594340)
DESCRIPTION:Bevacizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: HAIC 
 vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Be
 yond Up-To-Seven)\nEstimated primary completion: 30 May 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07594340
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06990516-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06990516)
DESCRIPTION:Bevacizumab\, phase 1/2\, Ovarian Cancer.\nStudy: SHR - A1811 I
 njection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer\n
 Estimated primary completion: 1 June 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06990516
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07805551-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07805551)
DESCRIPTION:Bevacizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A Study of
  HDM2017 Combination Therapy in Advanced Colorectal Cancer\nEstimated prim
 ary completion: August 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07805551
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07882056-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07882056)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: SBRT 
 Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for He
 patocellular Carcinoma\nEstimated primary completion: August 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07882056
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03942328-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT03942328)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Mod
 ified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Co
 mbined With Immune Checkpoint Inhibition After High-Dose External Beam Rad
 iation Therapy in Treating Patients With Unresectable Liver Cancer\nEstima
 ted primary completion: 31 August 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03942328
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04929223-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT04929223)
DESCRIPTION:Bevacizumab\, phase 1\, Colorectal Cancer.\nStudy: A Study Eval
 uating the Safety and Efficacy of Targeted Therapies in Subpopulations of 
 Patients With Metastatic Colorectal Cancer (INTRINSIC)\nEstimated primary 
 completion: 31 August 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04929223
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07791758-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300904
DTEND;VALUE=DATE:20300905
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07791758)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: A Clinical Trial of LBL-024 Co
 mbination Drug in Patients With Metastatic Colorectal Carcinoma\nEstimated
  primary completion: 4 September 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07791758
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: A Study Evaluating the Efficac
 y and Safety of Multiple Treatment Combinations in Patients With Metastati
 c or Locally Advanced Breast Cancer\nEstimated primary completion: 30 Sept
 ember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 3424005
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07239596-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07239596)
DESCRIPTION:Bevacizumab\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Phase I
 b/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment
  of Advanced Renal Cell Carcinom\nEstimated primary completion: December 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07239596
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07500298-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20301227
DTEND;VALUE=DATE:20301228
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT07500298)
DESCRIPTION:Bevacizumab\, phase 1\, Colorectal Cancer.\nStudy: Phase 1 Stud
 y Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line T
 reatment For Microsatellite Stable Metastatic Colorectal Cancer\nEstimated
  primary completion: 27 December 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07500298
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06791512-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT06791512)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: mFOLFOX6 + B
 evacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMM
 R/MSS CRC\nEstimated primary completion: 31 December 2030. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06791512
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06958419-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT06958419)
DESCRIPTION:Bevacizumab\, phase 2/3\, Colorectal Cancer.\nStudy: Node-Spari
 ng Short-Course Radiotherapy Plus Chemotherapy\, Bevacizumab and PD-1 Inhi
 bitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)\nEstimated pri
 mary completion: 31 December 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06958419
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06988852-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06988852)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: FOLFOX-HAIC as Conversion Treatm
 ent for Initially Unresectable Colorectal Liver Metastasis\nEstimated prim
 ary completion: 31 December 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06988852
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07334301-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07334301)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: A Multi-Arm\, Platform Trial F
 or Relapsed Neuroblastoma\nEstimated primary completion: 31 December 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07334301
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06543576-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06543576)
DESCRIPTION:Bevacizumab\, phase 1/2\, Cervical Cancer.\nStudy: External Bea
 m Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy 
 for the Treatment of Stage IVB Cervical Cancer\nEstimated primary completi
 on: 31 January 2031. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06543576
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07271355-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07271355)
DESCRIPTION:Bevacizumab\, phase 3\, Colorectal Cancer.\nStudy: Pressurized 
 Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment 
 of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases\,
  The IMPACT Trial\nEstimated primary completion: 28 February 2031. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07271355
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07585279-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT07585279)
DESCRIPTION:Bevacizumab\, phase 2/3\, Colorectal Cancer.\nStudy: A Clinical
  Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Color
 ectal Cancer\nEstimated primary completion: 28 February 2031. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07585279
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647653-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07647653)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Fluzoparib + Be
 vacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positiv
 e Advanced Ovarian Cancer\nEstimated primary completion: 28 February 2031.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07647653
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07346157-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07346157)
DESCRIPTION:Bevacizumab\, phase 1/2.\nStudy: Liothyronine in Combination Wi
 th BIT Regimen for Medulloblastoma With or Without Minimal Residual Diseas
 e\nEstimated primary completion: 31 March 2031. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07346157
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06725121-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06725121)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Usi
 ng Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Tr
 ansplant\nEstimated primary completion: June 2031. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06725121
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018947-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07018947)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Study
  to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Ne
 oadjuvant Plus Adjuvant Treatment in HCC\nEstimated primary completion: Ju
 ne 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0701
 8947
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743164-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07743164)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: A Clinical Tria
 l of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Partici
 pants With Ovarian Cancer Who Have Progressed During Treatment With PARP-i
 nhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG
 -3142 / REJOICE-Ovarian05)\nEstimated primary completion: 31 August 2031. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07743164
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691762-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07691762)
DESCRIPTION:Bevacizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: A Stu
 dy of TACE in Combination With SHR-8068\, Adebrelimab\, and Bevacizumab Ve
 rsus TACE in Participants With Incurable Hepatocellular Carcinoma\nEstimat
 ed primary completion: September 2031. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07691762
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07813572-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07813572)
DESCRIPTION:Bevacizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: ZG005
  Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for
  Advanced Hepatocellular\nEstimated primary completion: September 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07813572
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897968-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Bevacizumab: Phase 1 readout est. (NCT07897968)
DESCRIPTION:Bevacizumab\, phase 1.\nStudy: GD2IL18CART Combined With Bevaci
 zumab for Relapsed and Refractory GD2-positive Solid Tumors\nEstimated pri
 mary completion: 30 September 2031. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07897968
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071714-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07071714)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: A Phase II S
 tudy of SHR-8068 Injection in Combination With Anti-tumor Therapies in Col
 orectal Cancer\nEstimated primary completion: October 2031. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07071714
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07216703-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20311029
DTEND;VALUE=DATE:20311030
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07216703)
DESCRIPTION:Bevacizumab\, phase 3\, Cervical Cancer.\nStudy: A Clinical Stu
 dy of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab 
 (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-
 036/TroFuse-036/GOG-3123/ENGOT-cx22)\nEstimated primary completion: 29 Oct
 ober 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 216703
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720180-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20311201
DTEND;VALUE=DATE:20311202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07720180)
DESCRIPTION:Bevacizumab\, phase 2\, Ovarian Cancer.\nStudy: Study of Autolo
 gous\, Metabolically Optimized\, CD137+ Tumor-Infiltrating Lymphocytes Fol
 lowed by Consolidative Oral Cyclophosphamide\, Bevacizumab\, and Pembroliz
 umab\nEstimated primary completion: 1 December 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07720180
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005570-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07005570)
DESCRIPTION:Bevacizumab\, phase 2.\nStudy: Short-course Radiotherapy Follow
 ed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and
  Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rec
 tal Cancer （SPARK）\nEstimated primary completion: 31 December 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07005570
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776691-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20320319
DTEND;VALUE=DATE:20320320
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07776691)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: A Study of Ralu
 dotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance T
 reatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006\, (ENGOT
 -ov102/GOG-3141/ REJOICE-Ovarian 04)\nEstimated primary completion: 19 Mar
 ch 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0777
 6691
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797283-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20320501
DTEND;VALUE=DATE:20320502
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07797283)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: Phase 3 Study o
 f INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maint
 enance Therapy in Ovarian Cancer Overexpressing Cyclin E1\nEstimated prima
 ry completion: 1 May 2032. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07797283
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05468359-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05468359)
DESCRIPTION:Bevacizumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Saf
 ety and Efficacy of Cyclophosphamide\, Sorafenib\, Bevacizumab\, and Atezo
 lizumab in Pediatric Solid Tumor Patients\nEstimated primary completion: J
 une 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054
 68359
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05862285-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20330301
DTEND;VALUE=DATE:20330302
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05862285)
DESCRIPTION:Bevacizumab\, phase 3.\nStudy: A Rollover Study for Participant
 s Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored 
 Study\nEstimated primary completion: 1 March 2033. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05862285
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472140-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT07472140)
DESCRIPTION:Bevacizumab\, phase 2/3\, Ovarian Cancer.\nStudy: PARP (Poly (A
 DP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in
  Homologous Recombination Deficient Primary Ovarian Cancer\, Fallopian-Tub
 e Cancer\, or Primary Peritoneal Cancer\nEstimated primary completion: 30 
 June 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 472140
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06580314-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20341231
DTEND;VALUE=DATE:20350101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT06580314)
DESCRIPTION:Bevacizumab\, phase 3\, Ovarian Cancer.\nStudy: Testing Olapari
 b for One or Two Years\, With or Without Bevacizumab\, to Treat Ovarian Ca
 ncer\nEstimated primary completion: 31 December 2034. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06580314
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05620771-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20400701
DTEND;VALUE=DATE:20400702
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT05620771)
DESCRIPTION:Bevacizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Thera
 sphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma T
 hat is High-risk\nEstimated primary completion: 1 July 2040. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05620771
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02487992-2008@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20430731
DTEND;VALUE=DATE:20430801
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT02487992)
DESCRIPTION:Bevacizumab\, phase 2\, Colorectal Cancer.\nStudy: The Study of
  CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With A
 dvanced Colorectal Cancer\nEstimated primary completion: July 2043. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT02487992
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
